A head-to-head trial comparing decades-old steroid, prednisone, and new steroid, vamorolone, finds both act on same pathways involved in controlling inflammation, but vamorolone doesn’t activate pathways involved in prednisone’s undesirable side effects, making it a candidate for long-term use.

A head-to-head trial comparing decades-old steroid, prednisone, and new steroid, vamorolone, finds both act on same pathways involved in controlling inflammation, but vamorolone doesn’t activate pathways involved in prednisone’s undesirable side effects, making it a candidate for long-term use.: https://ift.tt/2I9bVaE Read more... https://ift.tt/2prQqsU